July 2010

That human touch and caring makes a big difference for people

A drug that delivers paclitaxel in a novel way has yielded favorable results in a phase II trial of patients with advanced esophageal cancer, prompting the company developing the drug to plan a phase III trial.

Data from the phase III ZETA trial show that vandetanib (Zactima), a selective tyrosine kinase inhibitor, significantly slows the progression of advanced medullary thyroid carcinoma

In a phase III randomized trial, overall survival (OS) was more than 34% longer for patients with advanced melanoma who received the novel agent ipilimumab